Back to search results

Phase 2 Study of Multiple Treatments for Obesity or Overweight

This study is a Phase 2 "master protocol" designed to test several different investigational medications for chronic weight management. These medications include LY3305677, LY3841136, Tirzepatide, LY3549492, and LY3532226. You might be able to join if you are between 18 and 75 years old and have a body mass index (BMI) of 30 or higher, or a BMI of 27 to 30 with at least one weight-related health issue. You also need to have had a stable weight for the three months before the study. The main goal of this part of the study is to see how many participants are assigned to each specific treatment group. The study is currently unclear on its recruitment status and plans to enroll 1481 participants.

Study design
This is an interventional Phase 2 study, meaning participants will receive a specific treatment. It is a master protocol designed to evaluate multiple interventions within a single framework, with a planned enrollment of 1481 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, "Number of Participants Allocated to Each ISA," is measured from Baseline to Week 6. The record does not specify follow-up beyond this timeframe.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06143956

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
PHASE2Ages 18–75InterventionalScreening
Eli Lilly and Company
~1,481 participants
Updated 2026-08-06 on ClinicalTrials.gov
What's tested:LY3305677LY3841136TirzepatideLY3549492LY3532226Placebo

At a glance

Recruiting sites
47 of 54 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants Allocated to Each ISA
Measured over Baseline to Week 6

Conditions

Obesity
Overweight

Explore related trials

ObesityOverweight

Where it's being run

54 sites across 23 states
Texas7
Florida6
Arizona4
California4
New York4
North Carolina4
Argentina4
Illinois3

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
1-317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have a body mass index (BMI)
≥30 kilogram/square meter (kg/m²), or
≥27 kg/m² and \<30 kg/m², or with at least 1 weight-related comorbidity
Have had a stable body weight for the 3 months prior to randomization (\<5%) body weight gain and/or loss.

Exclusion

Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening.
Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
Have poorly controlled hypertension.
Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
Have any of the following cardiovascular conditions within 3 months prior to screening:
acute myocardial infarction
cerebrovascular accident (stroke)
unstable angina, or
hospitalization due to congestive heart failure.
Have a history of symptomatic gallbladder disease within the past 2 years.
Have a lifetime history of suicide attempts.

What this trial measures

  • Number of Participants Allocated to Each ISABaseline to Week 6

    Each ISA will detail the intervention specific analysis.